Cell and Gene Supply Chain Solutions Companies and Organizational Profile

Leaders in the Cell and Gene Supply Chain Solutions Market

• Thermo Fisher Scientific
• Lonza Group
• Cryoport, Inc.
• Marken (part of UPS)
• World Courier
• Xylogics, Inc.
• Patheon (part of Thermo Fisher Scientific)
• Recipharm AB
• Catalent, Inc.
• BioLife Solutions, Inc.
• Acelity / KCI (3M)
• JN Biosciences
• Envigo RMS
• VWR International
• PCI Pharma Services
• BioStorage Technologies
• GeneCure Biotech
• Cryogenic Control Solutions
• Paragon Bioservices
• Waisman Biomanufacturing

Company Profile

Thermo Fisher Scientific

Overview:

• Headquartered in Waltham, Massachusetts, USA

• Established in 2006 after Thermo Electron and Fisher Scientific merged.

• A global leader in scientific instrumentation, reagents, and consumables, specializing in lab products, clinical diagnostics, and life sciences.

Top Products:

• Mass spectrometry instruments

• PCR reagents

• Chromatography systems

Strength:

• Diverse product portfolio across scientific sectors

• Strong global presence with over 80,000 employees

• Leadership in biotechnology and pharmaceuticals

Mergers & Acquisitions:

• Acquired Life Technologies (2014), expanding its capabilities in life sciences.

• Acquired Patheon (2017), further enhancing its manufacturing capabilities in drug development.

Challenges:

• Intense competition in life sciences research tools

• Challenges in maintaining growth across all product segments

• Navigating regulatory complexities in multiple global markets

Innovation or Announcement:

• Launched new genome editing tools in 2025, focusing on CRISPR technology advancements.

• Increased investment in digital solutions for laboratories, improving efficiency and data integration.

Lonza Group

Overview:

• Headquartered in Basel, Switzerland

• Founded in 1897, Lonza is a leading global supplier of life sciences tools and services, particularly focused on biotechnology, pharmaceuticals, and healthcare.

Top Products:

• Cell and gene therapies

• Biologics manufacturing services

• Custom development services

Strength:

• Leading role in cell and gene therapy manufacturing

• Strong collaborations with pharmaceutical giants

• High-quality biologic and biosimilar products

Mergers & Acquisitions:

• Acquired Capsugel in 2017, expanding its pharmaceutical services.

• Recent investment in gene therapy infrastructure, improving production scalability.

Challenges:

• High capital investment required for biotech manufacturing

• Regulatory challenges in international markets

• Pressure to innovate faster in the cell therapy space

Innovation or Announcement:

• Expanded its cell and gene therapy manufacturing capacity in 2025.

• Announced strategic partnership with a global biopharma company to advance mRNA technology.

Cryoport, Inc.

Overview:

• Headquartered in Knoxville, Tennessee, USA

• Founded in 2008, Cryoport specializes in the transportation of temperature-sensitive biological products for the pharmaceutical and biotechnology industries.

Top Products:

• Cryogenic shipping solutions

• Cold chain logistics

• Cryoport Express

Strength:

• Industry leader in cryogenic logistics

• Comprehensive, global temperature-controlled shipping network

• Trusted by pharmaceutical companies for vaccine and gene therapy logistics

Mergers & Acquisitions:

• Acquired Cryoport Express (2020), strengthening its shipping network.

• Recent acquisition of Nordic Cold Storage, enhancing its European footprint.

Challenges:

• High cost of specialized storage and transportation

• Navigating the complexities of international shipping regulations

• Managing capacity for large-scale shipments

Innovation or Announcement:

• Developed new ultra-low temperature storage solutions in 2025.

• Expanded its temperature-controlled shipping solutions to support the COVID-19 vaccine distribution.

Marken (part of UPS)

Overview:

• Headquartered in Durham, North Carolina, USA

• Established in 1980, Marken is a global provider of logistics and supply chain solutions for the pharmaceutical, biotechnology, and life sciences industries.

Top Products:

• Clinical trial logistics services

• Global temperature-controlled shipping

• Cold chain solutions

Strength:

• Expertise in clinical trial management logistics

• Strong global presence with over 40 locations worldwide

• Integration with UPS for enhanced logistics capabilities

Mergers & Acquisitions:

• Acquired by UPS in 2016, expanding its capabilities in the pharmaceutical logistics sector.

• Recently expanded its offerings in temperature-controlled packaging.

Challenges:

• Competition with other pharmaceutical logistics providers

• Complexities in meeting regulatory requirements across different countries

• Rising demand for faster and more cost-effective logistics solutions

Innovation or Announcement:

• Launched a new real-time monitoring system for cold chain logistics in 2025.

• Announced expanded partnerships with leading pharmaceutical companies to improve supply chain efficiency.

World Courier

Overview:

• Headquartered in Richmond, Virginia, USA

• Founded in 1969, World Courier is a global provider of specialty logistics services, particularly focused on temperature-sensitive and life sciences shipments.

Top Products:

• Cold chain logistics services

• Clinical trial transportation

• Custom packaging solutions

Strength:

• Strong expertise in global logistics for life sciences

• Robust infrastructure for temperature-sensitive shipments

• Part of the AmerisourceBergen Corporation, offering strong industry ties

Mergers & Acquisitions:

• Acquired by AmerisourceBergen in 2014, significantly expanding its global footprint.

• Continual investment in cold chain infrastructure to meet increasing demand.

Challenges:

• Managing complex international regulatory compliance

• Maintaining operational efficiency as demand for cold chain logistics rises

• Competition from other specialty logistics providers

Innovation or Announcement:

• Introduced new cold chain tracking technology in 2025 for enhanced monitoring during transit.

• Announced expansion into emerging markets to support global pharmaceutical shipments.

Xylogics, Inc.

Overview:

• Headquartered in Lexington, Massachusetts, USA

• Established in 1990, Xylogics provides specialized cold storage and cryogenic storage solutions for the pharmaceutical and biotechnology industries.

Top Products:

• Cryogenic storage systems

• Cold storage containers

• Biorepository solutions

Strength:

• Expertise in cryogenic preservation

• Advanced technology for temperature monitoring

• Strong relationships with biotech research institutions

Mergers & Acquisitions:

• Acquired by BioLife Solutions in 2019, expanding its product range in cryogenic storage.

• Integrated new technologies to enhance storage solutions in 2025.

Challenges:

• High capital investment required for cold storage systems

• Navigating complex regulatory standards across different markets

• Expanding product lines to meet increasing demand in gene therapy

Innovation or Announcement:

• Launched a new line of cryogenic storage containers for gene therapy products in 2025.

• Expanded production capacity to meet growing demand in Asia.

Patheon (part of Thermo Fisher Scientific)

Overview:

• Headquartered in Durham, North Carolina, USA

• Founded in 1974, Patheon is a contract development and manufacturing organization (CDMO) serving the pharmaceutical industry.

Top Products:

• Biologics manufacturing services

• Drug formulation and packaging

• API manufacturing

Strength:

• Strong expertise in drug development and manufacturing

• A global network of manufacturing facilities

• Acquired by Thermo Fisher in 2017, enhancing its capabilities in pharmaceuticals

Mergers & Acquisitions:

• Acquired by Thermo Fisher in 2017, significantly expanding its capacity and services.

• Recently expanded its biologics manufacturing capabilities to meet rising demand.

Challenges:

• Navigating regulatory hurdles in different global markets

• Increasing competition from other CDMOs

• Maintaining operational efficiency while scaling production

Innovation or Announcement:

• Introduced a new continuous manufacturing platform in 2025.

• Announced major investments to expand biologics production in North America.

Recipharm AB

Overview:

• Headquartered in Stockholm, Sweden

• Founded in 1995, Recipharm is a leading CDMO providing services to the pharmaceutical and biotechnology sectors.

Top Products:

• Oral solid dosage formulations

• Sterile products manufacturing

• Biologics development services

Strength:

• Strong focus on the production of both small and large molecules

• Global manufacturing presence with over 30 facilities

• Extensive experience in biologics and complex drugs

Mergers & Acquisitions:

• Acquired by the EQT Private Equity Group in 2015, expanding its international footprint.

• Recently acquired a facility in Spain to increase its sterile product manufacturing capacity.

Challenges:

• Competition from other established CDMOs

• Regulatory complexities in biologics manufacturing

• Rising cost pressures from raw materials

Innovation or Announcement:

• Expanded its biologics manufacturing capabilities in 2025.

• Partnered with a leading pharmaceutical company for the development of a new vaccine.

Market Growth

The global cell and gene supply chain solutions market size is calculated at US$ 3.54 billion in 2024, grew to US$ 4.09 billion in 2025, and is projected to reach around US$ 14.95 billion by 2034. The market is expanding at a CAGR of 15.54% between 2025 and 2034.

What are the Trends in the Market?

Rising CDMOs & CROs: Cell and gene therapies are gaining significant attention due to their potential in curing rare diseases and delivering better outcomes than other therapeutics. Due to the rising demand pharmaceutical and biotech companies face challenges in their supply chain and logistics processes. Due to this, a lot of CDMOs and CROs are entering into the cell and gene supply chain solutions market to provide supply chain solutions to pharma and biotech companies.

For instance,

• In June 2024, a strategic partnership was announced today by Cryoport, Inc., a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine Co., Ltd., a global contract development and manufacturing organisation for cell and gene therapies. The partnership will offer fully integrated logistics and manufacturing services to pharmaceutical and biotechnology companies for regenerative medicine products in order to support the advancement of these treatments.

Latest Announcements by Industry Leaders

In January 2025, although cell and gene therapy is developing rapidly, the industry still uses antiquated, laborious methods for sterile processing, such as tube welding or biosafety cabinets, according to Troy Ostreng, Senior Product Manager for CPC's biopharmaceutical division. To create a sterile flow route, customers may now simply snap the connection halves together in CGT processing components that come with the MicroCNX Nano connectors. This is a significant development for applications of CGT.

Recent Developments in the Market

• In October 2024, in order to assist cell and gene therapy firms in Brazil, Colombia, and Mexico with automated production, the medical technology company Terumo Blood and Cell Technologies (Terumo BCT) is growing its product line in Latin America.
• In October 2024, the InspiroGeneTM by McKesson ("InspiroGene"), a specialised company devoted only to assisting in the commercialisation of cell and gene therapies (CGTs), was launched today by McKesson Corporation.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com